Hoth Therapeutics Inc

HOTH

Company Profile

  • Business description

    Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

  • Contact

    1177 Avenue of the Americas
    5th Floor, Suite 5066
    New YorkNY10036
    USA

    T: +1 646 756-2997

    https://www.hoththerapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    3

Stocks News & Analysis

stocks

ASX retail share remains cheap despite weaker earnings

Weaker profit result drives cut to fair value yet shares remain undervalued.
stocks

Lowering profit forecasts on Aussie airlines

The impact of the oil price surge.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,712.8044.300.51%
CAC 407,681.8287.49-1.13%
DAX 4022,236.77376.20-1.66%
Dow JONES (US)45,960.11469.38-1.01%
FTSE 1009,890.6781.50-0.82%
HKSE24,951.8895.450.38%
NASDAQ21,408.08521.74-2.38%
Nikkei 22553,373.07230.58-0.43%
NZX 50 Index12,935.3941.60-0.32%
S&P 5006,477.16114.74-1.74%
S&P/ASX 2008,516.3044.700.53%
SSE Composite Index3,913.7224.640.63%

Market Movers